Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?  Amalia Gastaldelli, Giulio Marchesini  Journal of Hepatology  Volume 64, Issue 2, Pages 262-264 (February 2016) DOI: 10.1016/j.jhep.2015.11.031 Copyright © 2015 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Schematic representation of the mechanisms explaining the metabolic effects of liraglutide leading to an improvement in hepatic parameters. DNL, de novo lipogenesis; FFA, free fatty acids; GLP-1, glucagon-like peptide-1; GNG, gluconeogenesis; MCP-1, monocyte chemoattractant protein-1. Journal of Hepatology 2016 64, 262-264DOI: (10.1016/j.jhep.2015.11.031) Copyright © 2015 European Association for the Study of the Liver Terms and Conditions